Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 833.

https://doi.org/10.1182/blood.V130.Suppl_1.833.833

Published: 2017

Journal Articles

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Francisco Javier Peñalver Párraga, José Antonio Márquez Navarro, Soledad Durán Nieto, Pilar Giraldo Castellano, Carlos Montalbán Sanz, María José Ramírez Sánchez, Juan-Manuel Sancho Cia, María José Terol Castera, Francisco Javier Capote Huelva, Antonio Gutiérrez García, Blanca Sánchez González, Antonio Salar Silvestre, Miguel Canales Albendea, MD PhD, María Dolores Caballero Barrigón

Blood (2016) 128 (22): 1788.

https://doi.org/10.1182/blood.V128.22.1788.1788

Published: 2016

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MD PhD, Anna Sureda, MD PhD, Ana Pilar Gonzalez, MD, Fatima De la Cruz, MD PhD, Blanca Sanchez-Gonzalez, MD PhD, Antonia Rodriguez, MD PhD, Eva Domingo-Domenech, MD, Moreno Miriam, MD, Moreno Miriam, MD, Javier Lopez, Sr., MD PhD, Piñana Luis Jose, Gabriela Rodríguez, MD PhD, Miguel Canales, MD PhD, Antonio Gutierrez, MD PhD, Maria Dolores Caballero, MD PhD, Carmen Martinez, MD PhD

Blood (2016) 128 (22): 1109.

https://doi.org/10.1182/blood.V128.22.1109.1109

Published: 2016

Journal Articles

Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma

Sara Alonso, MD, Miguel Alcoceba, Oscar Blanco, Julio Davila, MD, Juan Carlos Caballero, MD, Luis Garcia, Oscar Ferre, Felix Lopez-Cadenas, Nerea Arratibel, Alvaro Veiga, Monica Baile, Oriana Lopez, Estefania Perez, Maria Dolores Caballero, MD PhD, Marcos González, MD PhD, Consuelo Del Cañizo, MD PhD, Maria Belen Vidriales, MD PhD, Alejandro Martin, MD PhD

Blood (2015) 126 (23): 3871.

https://doi.org/10.1182/blood.V126.23.3871.3871

Published: 2015

Journal Articles

Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MDPhD, Anna Sureda, MD PhD, Sara Alonso-Alvarez, MD, Ana Pilar Gonzalez, MD, Antonia Rodriguez, MD PhD, Antonio Salar, MD PhD, Fatima de la Cruz, MD, Eva Domingo, MD, Miriam Moreno, MD, Javier Lopez, Sr., MD PhD, Jose Luis Piñana, MD, Gabriela Rodriguez, Miguel Canales, Antonio Manuel Gurierrez, MD, Armando López-Guillermo, MD, María Dolores Caballero, MD PhD, Silvia Jimenez, BsC, Carmen Martinez, MD PhD

Blood (2015) 126 (23): 582.

https://doi.org/10.1182/blood.V126.23.582.582

Published: 2015

Journal Articles

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Blood (2015) 126 (23): 3944.

https://doi.org/10.1182/blood.V126.23.3944.3944

Published: 2015

Journal Articles

Clinical Impact of CD8+ Cells in Hodgkin Lymphoma Lymphadenopaties. Contribution of Flow Cytometry

Sara Alonso, MD, Maria Belen Vidriales, MD PhD, Maria Dolores Caballero, MD PhD, Oscar Blanco, J Galende, Maria Jesús Peñarrubia, MD PhD, Esther Zato, Abelardo Barez, Julio Davila, Juan Carlos Caballero, MD, Alberto Orfao, MD PhD, Marcos González, MD PhD, Ramon Garcia-Sanz, MD PhD

Blood (2015) 126 (23): 1442.

https://doi.org/10.1182/blood.V126.23.1442.1442

Published: 2015

Journal Articles

Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study

Blood (2015) 126 (23): 1508.

https://doi.org/10.1182/blood.V126.23.1508.1508

Published: 2015

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Blood (2014) 124 (21): 3980.

https://doi.org/10.1182/blood.V124.21.3980.3980

Published: 2014

Journal Articles

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Giuseppe Visani, Pietro Maria Stefani, Saveria Capria, Lara Malerba, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, Filippo Gherlinzoni, Roberta Gonella, Marco Gobbi, Armando Santoro, Felicetto Ferrara, Marco Rocchi, Enrique M. Ocio, Maria Dolores Caballero, Federica Loscocco, Alessandro Isidori

Blood (2014) 124 (19): 3029–3031.

https://doi.org/10.1182/blood-2014-08-596668

Published: 2014

Journal Articles

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Blood (2014) 123 (12): 1864–1869.

https://doi.org/10.1182/blood-2013-11-537993

Published: 2014

Includes: Supplemental data

Journal Articles

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Blood (2013) 122 (21): 2134.

https://doi.org/10.1182/blood.V122.21.2134.2134

Published: 2013

Journal Articles

The Combination of the EBMT Score and the HCT-CI Is Not Better Than the HCT-CI Alone in the Prediction of NRM and OS in Patients Undergoing Allogeneic Hematopoietic Transplantation with Reduced-Toxicity Conditioning

Pere Barba, David Valcarcel, MD, Lucía López-Corral, MD, Francesc fernandez-Aviles, Rodrigo Martino, MD, PhD, Monica Cabrero, Montserrat Rovira, jose Luis Pinana, Salut Brunet, Enric Carreras, MD, PhD, maria Dolores Caballero, Jorge Sierra, MD

Blood (2012) 120 (21): 1925.

https://doi.org/10.1182/blood.V120.21.1925.1925

Published: 2012

Journal Articles

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Blood (2011) 118 (12): 3419–3425.

https://doi.org/10.1182/blood-2011-04-351924

Published: 2011

Journal Articles

Front-Line Autologous Stem Cell Transplantation (ASCT) in Primary Mediastinal Large B-Cell Lymphoma: The GEL-TAMO Experience.

Jose Rodriguez, Eulogio Conde, Antonio Gutierrez, Juan Carlos Garcia-Ruiz, Juan Jose Lahuerta, Maria Rosario Varela, Encarnacion Perez-Equiza, Julian Marin, Carmen Albo, Maria Dolores Caballero

Blood (2006) 108 (11): 3056.

https://doi.org/10.1182/blood.V108.11.3056.3056

Published: 2006

Journal Articles

Front-Line Consolidation with Autologous Stem Cell Transplantation in Patients with Nodal Aggressive Peripheral T-Cell Lymphoma (PTCL). A Prospective Study of the GEL-TAMO.

Jose Rodriguez, MD, Eulogio Conde, MD, Antonio Gutierrez, MD, Reyes Arranz, MD, Angel Leon, MD, Julian Marin, MD, Maurizio Bendandi, MD, Carmen Albo, MD, Maria Dolores Caballero, MD

Blood (2006) 108 (11): 2463.

https://doi.org/10.1182/blood.V108.11.2463.2463

Published: 2006

Journal Articles

Prolonged Survival in Patients with Angioimmunoblastic T-Cell Lymphoma (AIL) after High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). The GELTAMO Experience.

Blood (2005) 106 (11): 2082.

https://doi.org/10.1182/blood.V106.11.2082.2082

Published: 2005

Journal Articles

The MYOCAN Study. A Phase II Study of Cyclophosphamide, Oncovin, Myocet™, and Prednisone Plus Rituximab (R-COMP) in the Treatment of Elderly Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL).

Massimo Federico, Martin J.S. Dyer, Maria Dolores Caballero, Claire Reilly, Eckhard Thiel

Blood (2004) 104 (11): 4586.

https://doi.org/10.1182/blood.V104.11.4586.4586

Published: 2004

Journal Articles

Secondary Malignancies after Autologous Stem Cell Transplantation for Hodgkin’s Lymphoma: Incidence and Analysis of Risk Factors.

Blood (2004) 104 (11): 60.

https://doi.org/10.1182/blood.V104.11.60.60

Published: 2004

NARROW

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma

Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Clinical Impact of CD8+ Cells in Hodgkin Lymphoma Lymphadenopaties. Contribution of Flow Cytometry

Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

The Combination of the EBMT Score and the HCT-CI Is Not Better Than the HCT-CI Alone in the Prediction of NRM and OS in Patients Undergoing Allogeneic Hematopoietic Transplantation with Reduced-Toxicity Conditioning

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Front-Line Autologous Stem Cell Transplantation (ASCT) in Primary Mediastinal Large B-Cell Lymphoma: The GEL-TAMO Experience.

Front-Line Consolidation with Autologous Stem Cell Transplantation in Patients with Nodal Aggressive Peripheral T-Cell Lymphoma (PTCL). A Prospective Study of the GEL-TAMO.

Prolonged Survival in Patients with Angioimmunoblastic T-Cell Lymphoma (AIL) after High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). The GELTAMO Experience.

The MYOCAN Study. A Phase II Study of Cyclophosphamide, Oncovin, Myocet™, and Prednisone Plus Rituximab (R-COMP) in the Treatment of Elderly Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL).

Secondary Malignancies after Autologous Stem Cell Transplantation for Hodgkin’s Lymphoma: Incidence and Analysis of Risk Factors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only